270: Your guide to Wegovy’s blockbuster heart study
The Readout Loud
00:00
Novo's Acquisition of Inversago Targets the Cannabinoid Receptor CB1
Novo announced this morning that they will be acquiring a small biotech called Inversago, which is developing an oral drug that targets the cannabinoid receptor CB1. Novo isn't the only one looking at approaches outside of GLP1. Eli Lilly said that it's going to acquire Versanis, which is another biotech that's developing a monoclonal antibody that aims to cut fat while preserving muscle mass.
Transcript
Play full episode
